LU90941I2 - Combinaison de budénoside et de formoterol et/ou de leurs dérivés pharmaceutiquement acceptables - Google Patents

Combinaison de budénoside et de formoterol et/ou de leurs dérivés pharmaceutiquement acceptables

Info

Publication number
LU90941I2
LU90941I2 LU90941C LU90941C LU90941I2 LU 90941 I2 LU90941 I2 LU 90941I2 LU 90941 C LU90941 C LU 90941C LU 90941 C LU90941 C LU 90941C LU 90941 I2 LU90941 I2 LU 90941I2
Authority
LU
Luxembourg
Prior art keywords
formoterol
budesonide
combination
pharmaceutically acceptable
acceptable derivatives
Prior art date
Application number
LU90941C
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26129933&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90941(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP1992/002826 external-priority patent/WO1993011773A1/fr
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LU90941I2 publication Critical patent/LU90941I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LU90941C 1991-12-18 2002-07-31 Combinaison de budénoside et de formoterol et/ou de leurs dérivés pharmaceutiquement acceptables LU90941I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP91311761 1991-12-18
PCT/EP1992/002826 WO1993011773A1 (fr) 1991-12-18 1992-12-07 Nouvelle combinaison de formoterol et de budesonide
EP92924683A EP0613371B1 (fr) 1991-12-18 1992-12-07 Nouvelle combinaison de formoterol et de budesonide

Publications (1)

Publication Number Publication Date
LU90941I2 true LU90941I2 (fr) 2002-09-30

Family

ID=26129933

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90941C LU90941I2 (fr) 1991-12-18 2002-07-31 Combinaison de budénoside et de formoterol et/ou de leurs dérivés pharmaceutiquement acceptables

Country Status (3)

Country Link
EP (3) EP1101493A3 (fr)
LU (1) LU90941I2 (fr)
NL (1) NL300094I2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
ITMI20130571A1 (it) 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US10449147B2 (en) * 2014-10-08 2019-10-22 Zambon S.P.A. Pharmaceutical composition containing budesonide and formoterol

Also Published As

Publication number Publication date
NL300094I1 (nl) 2002-09-02
EP1101493A3 (fr) 2004-01-14
EP0613371B1 (fr) 2002-03-06
EP1101493A2 (fr) 2001-05-23
NL300094I2 (nl) 2003-02-03
EP0613371A1 (fr) 1994-09-07
EP1086697A2 (fr) 2001-03-28

Similar Documents

Publication Publication Date Title
LU91205I2 (fr) Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
NO305537B1 (no) Farmas°ytisk preparat inneholdene et definert lipidsystem, og anvendelse av lipidsystemet
NO914667L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylderivater
EE05661B1 (et) Formoterooli ja budesoniidi sisaldava ravimkoostise kasutamine astma „gedate seisundite v„ltimiseks v?i raviks
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
NO914036L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater
NO985720D0 (no) Aerosol legemiddelformuleringer av formoterol
PT862431E (pt) Utilizacao de uma formulacao farmaceutica pediatrica que compreende amoxicilina e clavulanato
ITRM920270A1 (it) Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale.
MX9201154A (es) Derivados novedosos de 2-carboxiindoles que tienen actividad farmaceutica.
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
NO892820L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive amidino-og guanidino-derivater.
NO940027L (no) Fremgangsmaate for fremstilling av derivater av B-fenylisorerin og derivatenes anvendelse
ITTO920303A0 (it) "composizione farmaceutica antiinfiammatoria"
LU90941I2 (fr) Combinaison de budénoside et de formoterol et/ou de leurs dérivés pharmaceutiquement acceptables
NO943596D0 (no) Sanitetsbind med barriereorganer
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
FI961380A (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
FR2505826B1 (fr) Derives d'isoprenylamine et compositions pharmaceutiques preparees avec ces derives
DE69532819D1 (de) Kohlenhydrate derivate und die enthaltende zusammensetzungen
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables
BR9509055A (pt) Imidazoloquinoxalinona uso da mesma e composiçao farmacêutica